Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Blood (2023) 141 (4): 391–405.

https://doi.org/10.1182/blood.2022016892

Published: 2023

Includes: Supplemental data

Journal Articles

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Blood (2021) 138 (18): 1705–1720.

https://doi.org/10.1182/blood.2020010572

Published: 2021

Includes: Supplemental data

Journal Articles

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Blood (2021) 137 (18): 2495–2508.

https://doi.org/10.1182/blood.2020008414

Published: 2021

Includes: Supplemental data

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

Antonio Sacco, RN, Cinzia Federico, PhD, Arianna Giacomini, PhD, Cinzia Caprio, PhD, Federica Maccarinelli, PhD, Katia Todoerti, PhD, Vanessa Favasuli, Antonella Anastasia, MD, Marina Motta, MD, Giuseppe Rossi, MD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Antonino Neri, MD, Roberto Ronca, PhD, Chiara Cattaneo, MD, Alessandra Tucci, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MDPhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136523

Published: 2020

Journal Articles

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

Eugenio Morelli, MD, Mariateresa Fulciniti, PhD, Mehmet Kemal Samur, PhD, Caroline Ribeiro, PhD, Leon Wert-Lamas, PhD, Annamaria Gulla, MD, Anil Aktas Samur, PhD, Cinzia Federico, PhD, Francesca Scionti, PhD, Yao Yao, PhD, Nicola Amodio, PhD, Giada Bianchi, MD, Yu-Tzu Tai, PhD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD, Carl D. Novina, MD PhD, Massimo Loda, MD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 317.

https://doi.org/10.1182/blood-2019-130730

Published: 2019

Journal Articles

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3104.

https://doi.org/10.1182/blood-2019-124391

Published: 2019

Journal Articles

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Cinzia Federico, PhD, Antonio Sacco, RN, Katia Todoerti, PhD, Arianna Giacomini, PhD, Gaia C Ghedini, PhD, Gaetana Lanzi, PhD, Marina Motta, MD, Antonella Anastasia, MD, Vanessa Favasuli, Roberto Ronca, PhD, Silvia Giliani, PhD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Giuseppe Rossi, Antonino Neri, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MD PhD

Blood (2019) 134 (Supplement_1): 1822.

https://doi.org/10.1182/blood-2019-126554

Published: 2019

Journal Articles

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃ¶m Macroglobulinemia

Nicola Amodio, PhD, Giada Juli, PhD, Eugenio Morelli, MD, Maria Angelica Stamato, PhD, Maria Eugenia Gallo Cantafio, PhD, Cinzia Federico, PhD, Katia Todoerti, PhD, Emanuela Altomare, Katia Grillone, PhD, Marco Rossi, MD, Michele Cea, MD, Antonino Neri, MD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2018) 132 (Supplement 1): 1585.

https://doi.org/10.1182/blood-2018-99-110928

Published: 2018

Journal Articles

Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications

Eugenio Morelli, MD, Mariateresa Fulciniti, PhD, Mehmet Kemal Samur, PhD, Francesca Scionti, Annamaria Gulla, MD, Nicola Amodio, PhD, Giada Bianchi, MD, Tommaso Perini, MD, Cinzia Federico, PhD, Michael A Lopez, Maria Teresa Di Martino, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD, Kenneth Anderson, MD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 1925.

https://doi.org/10.1182/blood-2018-99-119572

Published: 2018

Journal Articles

Overcoming Drug Resistance in Myeloma By Synchronized Delivery of Therapeutic and Bone Marrow Disrupting Agents By Nanoparticles Targeting Tumor-Associated Endothelium

Cinzia Federico, PhD, Barbara Muz, PhDMSc, Jennifer Sun, BSc, Kinan Alhallak, BSc, Justin King, Daniel R. Kohnen, MBA, Mark A. Fiala, BS, Aldo M. Roccaro, MDPhD, Ravi Vij, MBBS, Abdel Kareem Azab, PhD

Blood (2018) 132 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2018-99-118251

Published: 2018

Journal Articles

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Blood (2018) 132 (10): 1050–1063.

https://doi.org/10.1182/blood-2018-03-836601

Published: 2018

Includes: Supplemental data

Journal Articles

Enhancing Proteasome-Inhibitory Activity and Specificity of Bortezomib By Endocytosis-Mediated Uptake of CD38 Targeted Nanoparticles in Multiple Myeloma

Pilar De La Puente, PhD M.Sc, Abbey Jin, Micah John Luderer, BS, MS, Christopher Egbulefu, Barbara Muz, PhDMSc, Cinzia Federico, PhD, Justin King, Daniel Kohnen, Noha Nabil Salama, PhD, Samuel Achilefu, Ravi Vij, MDMBA, Abdel Kareem Azab, PhD

Blood (2017) 130 (Supplement 1): 1876.

https://doi.org/10.1182/blood.V130.Suppl_1.1876.1876

Published: 2017

Journal Articles

Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease

Marco Rossi, Emanuela Altomare, Nicola Amodio, PhD, Maria Teresa Di Martino, Marco Gaspari, Domenico Taverna, Domenica Scumaci, Francesco Conforti, Daniele Caracciolo, Cirino Botta, Cinzia Federico, Annamaria Gullà, Eugenio Morelli, Francesca Scionti, Mariamena Arbitrio, MD, Paola Critelli, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2017) 130 (Supplement 1): 4380.

https://doi.org/10.1182/blood.V130.Suppl_1.4380.4380

Published: 2017

Journal Articles

Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines

Lavinia Biamonte, PhD, Cinzia Federico, PhD, Eugenio Morelli, MD, Emanuela Leone, PhD, Maria Eugenia Gallo Cantafio, PhD, Maria Teresa Di Martino, Nicola Amodio, PhD, Marco Rossi, MD, Antonino Neri, Pr, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2015) 126 (23): 3019.

https://doi.org/10.1182/blood.V126.23.3019.3019

Published: 2015

NARROW

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃ¶m Macroglobulinemia

Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications

Overcoming Drug Resistance in Myeloma By Synchronized Delivery of Therapeutic and Bone Marrow Disrupting Agents By Nanoparticles Targeting Tumor-Associated Endothelium

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Enhancing Proteasome-Inhibitory Activity and Specificity of Bortezomib By Endocytosis-Mediated Uptake of CD38 Targeted Nanoparticles in Multiple Myeloma

Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease

Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only